Solutions
Neurosurgeon operating with intraoperative brain imaging
Neurosurgery
Functional brain-network data for complex neurosurgical decisions.
Clinician reviewing brain imaging on a monitor
Neurology
Objective brain function insights for more informed neurological care.
Older couple walking outdoors
Brain Health
Supporting healthier brains through earlier insight.
Clinicians reviewing a brain scan on a monitor
Clinical Research
Empowering the next generation of neuroscience research.
TechnologyResourcesQuantalX NeuroscienceReimbursementAboutContact us
QuantalX Neuroscience
All resources
Peer-reviewed publication
Clinical EEG and Neuroscience
2026

Prefrontal and Occipital Network Excitability Differences in Dementia with Lewy Bodies and Alzheimer's Disease

Bregman N, Zifman N, Fogel H, Abulher E, Maidan I, Shiner T

Clinical EEG and Neuroscience journal cover
Key finding

Responses to visual and prefrontal cortex stimulation differed between dementia with Lewy bodies and Alzheimer's disease, suggesting a non-invasive way to help tell the two apart.

Study design
Case-control study, TMS-EEG
Participants
12 DLB, 10 Alzheimer's disease and 17 healthy controls

Summary

Distinguishing dementia with Lewy bodies (DLB) from Alzheimer's disease (AD) remains a clinical challenge. This study used TMS-evoked potentials (TEPs), a non-invasive measure of neurophysiological changes, to compare network excitability in the two conditions.

Study design

  • Participants: 39 in total, 12 with DLB, 10 with AD and 17 age-matched healthy controls.
  • TEPs were recorded after stimulation of the dorsolateral prefrontal cortex (DLPFC), primary motor cortex (M1) and primary visual cortex (V1).

Key findings

  • Late global mean field potential (130–250 ms) after V1 stimulation was higher in DLB than in AD and in healthy controls (p = .001 for both comparisons).
  • The P60 amplitude after DLPFC stimulation differed between DLB and AD (p = .0013) and between DLB and controls (p = .0032).
  • DLPFC N45 amplitude correlated with motor symptom severity on the UPDRS-III (r = 0.9, p = .0002).
  • In AD, a relatively higher left-over-right DLPFC P30 amplitude correlated with poorer MoCA scores (r = −0.84, p = .002).

Authors' conclusions

The authors propose the DLPFC as a target for assessing motor symptom severity in DLB and cognitive impairment in AD, and suggest that DLPFC and V1 network characteristics offer a promising non-invasive method to distinguish DLB from AD and to monitor disease.

Read the full article

Bregman N, Zifman N, Fogel H, Abulher E, Maidan I, Shiner T. Prefrontal and Occipital Network Excitability Differences in Dementia with Lewy Bodies and Alzheimer's Disease. Clinical EEG and Neuroscience. 2026. doi:10.1177/15500594261452759

Summary prepared by QuantalX from the published abstract. All results are as reported by the authors. The full text is available from the publisher.

Bring brain function data into your practice

Talk to the QuantalX team about Delphi-MD™ in your clinical setting.

Request a demo
On this page
Section
Journal
Clinical EEG and Neuroscience
Year
2026
DOI
10.1177/15500594261452759
Licence
Copyright SAGE Publications. Summary by QuantalX
Read in the journal
QuantalX Neuroscience
Join our newsletter to stay up to date on clinical updates and company news.
By subscribing you agree to our Privacy Policy and provide consent to receive updates from our company.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Solutions
NeurosurgeryNeurologyBrain HealthClinical ResearchPsychiatry
Company
TechnologyPartner ZoneResourcesAbout UsContact
Follow us
Facebook
Instagram
X
LinkedIn
© 2026 Quantalx. All rights reserved.
Privacy PolicyTerms of Service
*All clinical interpretations of Delphi-MD™ assessments must be made by qualified healthcare professionals within the context of a full patient evaluation. The Delphi-MD™ system is intended to elicit, record, and analyze TMS-evoked brain potentials (TEPs) and provide quantitative output parameters compared against a normative reference database limited to ages 50–75. Adverse events during or after evaluation may include headache, nausea, dizziness, fatigue, insomnia, anxiety/agitation, back or neck pain, vomiting, tinnitus, migraine aura, and abnormal sensations. Delphi-MD™ is not intended to be relied upon solely to make or confirm a diagnosis. For more information, refer to the Delphi-MD™ user manual.
Schedule a Demo